Laura Galeazzi
Acute Care · Lancaster, CANPI 1982006748
Payments from drug & device makers
Across 80 payments — averaging $24.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$247
- Lilly USA, LLC$225
- Phathom Pharmaceuticals, Inc.$192
- AstraZeneca$143
- Otsuka America Pharmaceutical, Inc.$138
- Dexcom, Inc.$118
- plus $908 from 20 others
What the payments were for
- Food & beverage$1,970100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 10 | $247 |
| Lilly USA, LLC | 8 | $225 |
| Phathom Pharmaceuticals, Inc. | 4 | $192 |
| AstraZeneca | 8 | $143 |
| Otsuka America Pharmaceutical, Inc. | 5 | $138 |
| Dexcom, Inc. | 4 | $118 |
| Novo Nordisk | 5 | $100 |
| Boehringer Ingelheim | 4 | $98 |
| Regeneron Healthcare Solutions, Inc. | 3 | $93 |
| AbbVie | 3 | $77 |
| Sanofi Pasteur Inc. | 3 | $75 |
| Ascensia Diabetes Care US Inc. | 3 | $65 |
| Pfizer | 3 | $48 |
| Verity Pharmaceuticals Inc. | 2 | $47 |
| Corcept Therapeutics | 2 | $42 |
| Phadia US Inc. | 2 | $40 |
| Tolmar, Inc. | 2 | $39 |
| Insulet Corporation | 1 | $38 |
| Eisai Inc. | 1 | $31 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Bayer | 1 | $18 |
| Shield Therapeutics Inc | 1 | $18 |
| Verona Pharma, Inc. | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
| Organon | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VOQUEZNA$125
How this compares
$1,970 in reported general payments places this provider in the 80th percentile of 1,153 acute care providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 14 | $19,106 |
| JardianceEmpagliflozin | 12 | $13,460 |
| Trazodone Hcl | 15 | $1,099 |
| Olmesartan Medoxomil | 21 | $657 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 18 | $460 |
| Atorvastatin Calcium | 27 | $210 |
| Levothyroxine Sodium | 21 | $191 |
| Pantoprazole Sodium | 14 | $179 |
| Gabapentin | 17 | $173 |
| Amlodipine Besylate | 12 | $160 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 19 | $148 |
| Ondansetron OdtOndansetron | 15 | $116 |
| Metformin Hcl | 17 | $92 |
| Cephalexin | 13 | $51 |
| Meloxicam | 12 | $42 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $100 | $19,10614 claims |
| Boehringer IngelheimJardiance | $98 | $13,46012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,153 acute care providers in California.
Other acute care in Lancaster
- Leslie PetersenCamarillo$370K
- Joyce KhremianSan Dimas$73K
- Eleanor VierraSacramento$64K
- Frances DyLos Angeles$57K
- Savannah HarrisVentura$56K
- Kori Ann JohnstonLos Angeles$42K
- Caroline KwongOrange$42K
- Gregory KnutzenColton$41K
- Sunita BoparaiLos Angeles$37K
- Sherona BauLos Angeles$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.